Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice

被引:77
作者
Ebert, O [1 ]
Harbaran, S [1 ]
Shinozaki, K [1 ]
Woo, SLC [1 ]
机构
[1] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA
关键词
breast cancer; metastases; oncolytic virus; vesicular stomatitis virus; matrix protein mutant;
D O I
10.1038/sj.cgt.7700794
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In view of the limited success of available treatment modalities for metastatic breast cancer, alternative and complementary strategies need to be developed. Oncolytic vesicular stomatitis virus (VSV) is a promising novel therapeutic agent for the treatment of cancer. The aim of this study was to evaluate the potential of recombinant VSV containing the M51R mutation in the matrix ( M) protein gene administered intravenously as an effective and safe therapeutic agent for treating mice with experimental breast cancer metastases. Recombinant VSV( M51R)-LacZ was generated and characterized in vitro on human and murine breast cancer cells. Breast cancer metastases were established in immune-competent Balb/c mice by intravenous injection of syngeneic 4T1 cells. The vector was infused into the tumor-bearing animals via the tail vein, and productive infection of pulmonary breast cancer lesions was assessed by X-gal stainings of frozen lung sections. To evaluate potential systemic toxicity, histology of major organs and serum chemistries were analyzed. To assess effectiveness, buffer- or vector-treated tumor-bearing mice were followed for survival and the results were analyzed by the Kaplan-Meier method and the log-rank test. We found that VSV( M51R)-LacZ efficiently replicated and lysed human breast cancer cells but was partially attenuated in 4T1 cells in vitro. We also demonstrated that its maximum tolerated dose after intravenous infusion in normal Balb/c mice was elevated by at least 100-fold over that of the parental VSV vector containing the wild-type M gene. When VSV( M51R)-LacZ was repeatedly injected intravenously into mice bearing syngeneic 4T1 tumors, the virus was able to infect multiple breast cancer lesions in the lungs without apparent toxicities, which led to significant prolongation of animal survival ( P =. 003). In conclusion, systemic administration of M mutant VSV is both effective and safe in the treatment of experimental breast cancer metastases in immune-competent mice, suggesting that further development of this approach may have potential for clinical application in patients.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 35 条
[1]   Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis [J].
Ahmed, M ;
McKenzie, MO ;
Puckett, S ;
Hojnacki, M ;
Poliquin, L ;
Lyles, DS .
JOURNAL OF VIROLOGY, 2003, 77 (08) :4646-4657
[2]   Defective translational control facilitates vesicular stomatitis virus oncolysis [J].
Balachandran, S ;
Barber, GN .
CANCER CELL, 2004, 5 (01) :51-65
[3]   Vesicular stomatitis virus (VSV) therapy of tumors [J].
Balachandran, S ;
Barber, GN .
IUBMB LIFE, 2000, 50 (02) :135-138
[4]  
Bateman A, 2000, CANCER RES, V60, P1492
[5]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[6]  
CHARAN S, 1986, J IMMUNOL, V136, P3057
[7]   Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells [J].
Desforges, M ;
Charron, J ;
Bérard, S ;
Beausoleil, S ;
Stojdl, DF ;
Despars, G ;
Laverdière, B ;
Bell, JC ;
Talbot, PJ ;
Stanners, CP ;
Poliquin, L .
VIRUS RESEARCH, 2001, 76 (01) :87-102
[8]   Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer [J].
Ebert, O ;
Shinozaki, K ;
Kournioti, C ;
Park, MS ;
García-Sastre, A ;
Woo, SLC .
CANCER RESEARCH, 2004, 64 (09) :3265-3270
[9]  
Ebert O, 2003, CANCER RES, V63, P3605
[10]   Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease [J].
Fernandez, M ;
Porosnicu, M ;
Markovic, D ;
Barber, GN .
JOURNAL OF VIROLOGY, 2002, 76 (02) :895-904